Literature DB >> 19903587

Trends in antibiotic susceptibility of bloodstream pathogens in hospitalized patients in France, 1996 to 2007.

Jean-Winoc Decousser1, Brigitte Lamy, Patrick Pina, Pierre Yves Allouch.   

Abstract

Nationwide surveys of antimicrobial susceptibility of bacteria isolated from bloodstream infections are required to fit empiric therapy to recent trends and detect emerging resistance. We report the results of a French national prospective survey based on the College of Bacteriology-Virology and Hygiene study group network performed each October during the 1996 to 2007 period, with focus on Enterobacteriaceae (7708 isolates) and Staphylococcus aureus (2271 isolates). The most relevant antimicrobial susceptibilities trends were i) a decrease in fluoroquinolones susceptibility among Enterobacteriaceae (96-90%, P < 0.0001) and Escherichia coli isolates (98-89%, P < 0.0001), respectively, ii) the slight but significant decrease in cefotaxime susceptibility among E. coli (P = 0.016), and iii) the significant increase in gentamicin susceptibility among S. aureus strains (P = 0.016). This survey reports antibiotic susceptibility of bloodstream pathogens in France. The empiric use of fluoroquinolones in severe infections should be cautiously monitored by thorough clinical and microbiologic follow-up. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19903587     DOI: 10.1016/j.diagmicrobio.2009.10.007

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  2 in total

1.  Influence of referral bias on the clinical characteristics of patients with Gram-negative bloodstream infection.

Authors:  M N Al-Hasan; J E Eckel-Passow; L M Baddour
Journal:  Epidemiol Infect       Date:  2011-02-01       Impact factor: 2.451

2.  The microbiology of bacterial peritonitis due to appendicitis in children.

Authors:  O Obinwa; M Casidy; J Flynn
Journal:  Ir J Med Sci       Date:  2013-12-18       Impact factor: 1.568

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.